• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Kinnate Biopharma Inc. - Common Stock (NQ:KNTE)

    N/A UNCHANGED
    Last Price Updated: 4:00 PM EDT, Apr 2, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Kinnate Biopharma Inc. - Common Stock

    < Previous 1 2 3 4 Next >
    XOMA Corporation Announces Closing of Tender Offer
    Kinnate Stockholders to Receive $2.5879 Per Share in Cash Plus Contingent Value Right 
    From XOMA Corporation
    Via GlobeNewswire
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Agiliti, Inc. (NYSE – AGTI), Landos Biopharma, Inc. (Nasdaq – LABP), Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Kinnate Biopharma Inc. (Nasdaq – KNTE)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.
    Upon closing, XOMA anticipates adding approximately $9.5 million in cash to its balance sheet and several early-stage programs to potentially add to its royalty portfolio 
    From XOMA Corporation
    Via GlobeNewswire
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Whole Earth Brands, Inc. (Nasdaq – FREE), Kinnate Biopharma Inc. (Nasdaq – KNTE), Societal CDMO Check Corp. (Nasdaq –
    From Brodsky & Smith LLC
    Via GlobeNewswire
    KINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE
    From Kahn Swick & Foti, LLC
    Via Business Wire
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Whole Earth Brands, Inc. (Nasdaq – FREE), Kinnate Biopharma Inc. (Nasdaq – KNTE), Societal CDMO Check Corp. (Nasdaq – SCTL), California BanCorp (Nasdaq – CALB)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories
    From Kinnate Biopharma; Pierre Fabre Laboratories
    Via GlobeNewswire
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AVROBIO, Inc. (Nasdaq – AVRO), Whole Earth Brands, Inc. (Nasdaq – FREE), Kinnate Biopharma Inc. (Nasdaq – KNTE), California BanCorp (Nasdaq – CALB)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: VIZIO Holding Corp. (NYSE - VZIO), HireRight Holdings Corporation (NYSE – HRT), Kinnate Biopharma Inc. (Nasdaq – KNTE), California BanCorp (Nasdaq – CALB)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    KINNATE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE
    From Kahn Swick & Foti, LLC
    Via Business Wire
    Biotech Royalty Aggregator XOMA To Acquire Small Cancer-Drug Developer Kinnate Biopharma
    XOMA acquires Kinnate Biopharma for $2.3352 per share, with potential additional cash. The acquisition is expected to close in April 2024. 
    Via Benzinga
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: HireRight Holdings Corporation (NYSE – HRT), Kinnate Biopharma Inc. (Nasdaq – KNTE), AVROBIO, Inc. (Nasdaq – AVRO), California BanCorp (Nasdaq – CALB)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    KNTE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Kinnate Biopharma Inc. Is Fair to Shareholders
    From NEW YORK
    Via Business Wire
    Kinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per Share
    From Kinnate Biopharma
    Via GlobeNewswire
    XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right
    Upon closing, XOMA anticipates adding approximately $9.5 million in cash to its balance sheet and several early-stage programs to potentially add to its royalty portfolio 
    From XOMA Corporation
    Via GlobeNewswire
    Why Shapeways Holdings Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Shares of Shapeways Holdings, Inc. (NASDAQ: SHPW) tumbled during Wednesday’s session following downbeat results. 
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Intraday Session
     
    Via Benzinga
    Kinnate Biopharma Inc. (NASDAQ: KNTE) is One of Wednesday Morning’s Most Active Stocks
    Via Investor Brand Network
    Why is Cancer-Focused Kinnate Biopharma Stock Trading Higher Today?
    Kinnate Biopharma Inc's (NASDAQ: KNTE) board of directors received a letter from Foresite Capital Management and OrbiMed Advisors indicating their intent to explore and evaluate a potential acquisition... 
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
     
    Via Benzinga
    Kinnate Biopharma Inc. Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
    From Kinnate Biopharma
    Via GlobeNewswire
    Analysts Move To Sidelines For Cancer Player Kinnate Biopharma After Restructuring
    Monday, Kinnate Biopharma Inc (NASDAQ: KNTE) prioritized the exarafenib combination, KIN-8741, and discovery efforts around its  
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For September 19, 2023
     
    Via Benzinga
    Why Is Cancer Firm Kinnate Biopharma Stock Trading Lower Today?
    Kinnate Biopharma Inc (NASDAQ: KNTE) announced pipeline updates, a reprioritization plan, and workforce restructuring to  
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
     
    Via Benzinga
    Dell Technologies To Rally More Than 15%? Here Are 10 Other Analyst Forecasts For Tuesday
    Raymond James increased the price target for Vital Energy, Inc. (NYSE: VTLE) from $54 to $67. Raymond James analyst John Freeman maintained an Outperform rating. Vital Energy shares rose 0.5% to $54.37... 
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
    Pre-market stock movers are a hot topic on Tuesday as investors seek out the latest news on the biggest traders this morning! 
    Via InvestorPlace
    12 Health Care Stocks Moving In Monday's After-Market Session
     
    Via Benzinga
    Kinnate Biopharma Inc. Announces Pipeline Updates, Strategic Reprioritization and Workforce Restructuring
    From Kinnate Biopharma
    Via GlobeNewswire
    Kinnate Biopharma Inc. Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
    From Kinnate Biopharma
    Via GlobeNewswire
    < Previous 1 2 3 4 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.